Evgen Pharma's (LON:EVG) Dr Huw Jones talks to Proactive London about their latest interim results for the six months ended 30 September 2020.
Jones discusses the highlights which include the completion of first out-licensing deal with Juvenescence for use of Sulforadex® technology in non-pharmaceutical markets.
And patient recruitment has commenced in their STAR trial post the period end with data potentially available in Q4 2021.
Jones explains their business model which is to partner with large pharmaceuticals 'who can do the enormous trials that are necessary and take it to the market eventually as a medicine'.
